AbbVie, Genmab present new data for bispecific antibody epcoritamab

AbbVie (ABBV) and Genmab (GMAB) announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis. Updated data from this study include an optimized, step-up dosing schedule showing reduced incidence and severity of cytokine release syndrome, a notable side effect from immune-engaging cancer treatments. No new safety signals were detected. TEAEs leading to treatment discontinuation occurred in 19% of patients, and death related to TEAEs occurred in 13 patients.